The road to an effective HIV vaccine.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses.Cell reports · 2019
   Article
2. Pre-exposure prophylaxis of HIV: A right way to go or a long way to go?Artificial cells, nanomedicine, and biotechnology · 2016
   Review
3. Ending the HIV/AIDS epidemic in low- and middle-income countries by 2030: is it possible?F1000Research · 2016
   Review
4. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.Trials · 2014
   Article
5. Genotypes and transmitted drug resistance among treatment-naive HIV-1-infected patients in a northwestern province, China: trends from 2003 to 2013.PloS one · 2014
   Article
6. Social justice and HIV vaccine research in the age of pre-exposure prophylaxis and treatment as prevention.Current HIV research · 2013
   Article
7. Translational research insights from completed HIV vaccine efficacy trials.Journal of acquired immune deficiency syndromes (1999) · 2013
   Review
8. Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1).Therapeutic advances in vaccines · 2013
   Article
9. Infectious diseases: a call for manuscripts in an interdisciplinary era.International journal of clinical practice · 2013
   Article
10. Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccines.Retrovirology · 2012
    Review
11. HIV-1 Vaccine Trials: Evolving Concepts and Designs.The open AIDS journal · 2012
    Article
12. Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates.PloS one · 2012
    Article

Corrections and comments

• Comment on
  Immune-correlates analysis of an HIV-1 vaccine efficacy trial.2012
• Erratum issued

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as